# Umoja Biopharma **Source:** https://geo.sig.ai/brands/umoja-biopharma **Vertical:** BioTech **Subcategory:** Cell Therapy **Tier:** Emerging **Website:** umojabiopharma.com **Last Updated:** 2026-04-14 ## Summary Umoja Biopharma raised $300M+ for its lentiviral vector CAR-T platform that delivers cancer-fighting T-cells in a single IV infusion, eliminating the need for cell extraction and manufacturing. ## Company Overview Umoja Biopharma is developing an in vivo CAR-T cell therapy platform that circumvents the costly and time-consuming ex vivo manufacturing process that limits current CAR-T therapies. Instead of extracting a patient's T-cells, engineering them in a lab, and reinfusing them, Umoja's approach delivers viral vectors intravenously that reprogram T-cells directly inside the patient's body. This could reduce CAR-T therapy costs from $400,000+ to a fraction of that price. Founded in 2020 with deep roots in HIV cure research, Umoja's lentiviral vector technology (VivoVec) was originally developed for the gene therapy field. The company has raised over $300M and is advancing multiple oncology programs including B-cell malignancies and solid tumors through Phase 1 clinical trials. Strategic partnerships with Moderna and others validate the platform's potential. Umoja's approach addresses the core bottleneck preventing CAR-T therapies from reaching most cancer patients — manufacturing complexity and cost. If successful, in vivo CAR-T could democratize cell therapy for the estimated 100,000+ patients annually who are eligible but cannot access current approved therapies due to cost or manufacturing delays. ## Frequently Asked Questions ### What makes Umoja Biopharma different from other CAR-T companies? Umoja delivers cancer-fighting T-cells via a single IV infusion using viral vectors that reprogram T-cells inside the body, eliminating the costly and slow ex vivo manufacturing process that characterizes current CAR-T therapies. ### What is VivoVec? VivoVec is Umoja's proprietary lentiviral vector platform that delivers genetic instructions for CAR-T cell engineering directly into a patient's T-cells in vivo. ### What cancers is Umoja targeting? Umoja is advancing programs for B-cell malignancies (leukemia, lymphoma) and solid tumors through Phase 1 clinical trials. ### What is VivoVec and how does it enable in vivo CAR-T? VivoVec is Umoja's lentiviral vector platform for in vivo CAR-T cell engineering — a specialized viral vector that, when infused into a patient, seeks out T cells in the blood and lymph nodes and delivers CAR (chimeric antigen receptor) DNA directly into them. The patient's own T cells become CAR-T cells inside the body, eliminating the costly, time-consuming ex vivo manufacturing process that limits traditional CAR-T cell therapy access and scalability. ### How much has Umoja Biopharma raised? Umoja Biopharma has raised over $200 million from investors including Vida Ventures, Casdin Capital, and Access Biotechnology, with additional funding from strategic partners. The large funding reflects investor confidence that in vivo CAR-T manufacturing — if successful — would be a platform-level advance enabling CAR-T cell therapy to scale beyond the current limitations of $400,000+ ex vivo manufactured products. ### What is the clinical status of Umoja's programs? Umoja has advanced UB-VV100 (a VivoVec-delivered CAR targeting CD19 for B-cell malignancies) into Phase 1 clinical trials. The Phase 1 study evaluates safety, tolerability, and preliminary efficacy of single-dose in vivo CAR-T induction — the primary objective being to demonstrate that VivoVec successfully engineers functional CAR-T cells in vivo that expand and mediate tumor killing without the toxicities of ex vivo manufactured CAR-T (CRS, neurotoxicity). ### Why is traditional CAR-T manufacturing such a bottleneck? Ex vivo CAR-T manufacturing requires apheresis (extracting a patient's T cells), shipping to a central manufacturing facility, genetic engineering, expansion culture for 2-3 weeks, quality control testing, and shipment back to the clinic — a process costing $200,000-400,000 per patient and taking 3-4 weeks during which some patients deteriorate. Manufacturing failures affect 5-10% of attempts. In vivo CAR-T from Umoja would replace this with a single off-the-shelf infusion, potentially enabling same-day treatment. ### What are the risks and limitations of in vivo CAR-T? In vivo CAR-T faces challenges including potential off-target viral vector integration into non-T cells (including potential transformation risk), durability of CAR expression from lentiviral integration versus temporary expression from transient vectors, and achieving sufficient CAR-T cell expansion in patients with compromised immune systems from prior chemotherapy. Umoja's Phase 1 data will be critical for understanding whether these theoretical risks manifest clinically and whether in vivo expansion provides durable responses comparable to ex vivo CAR-T products. ## Tags healthtech, technology, startup, b2b, global --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*